Home Magazine Editions Volume 9, Issue No. 2, April 2022

Volume 9, Issue No. 2, April 2022

The focus of the April 2022 issue is centred on the rapidly evolving area of minimal residual disease but as was pointed out in one of our interviews, when you’re looking at numbers close to a million or so cancer cells it’s hard to argue there is anything minimal about that analysis at all. We should, however, be optimistic as MRD is having a significant impact on how we run clinical trials and how we are now able to stratify patients, not least, how we create a more comprehensive picture of predisposition and evolution of cancer, creating an end-to-end solution for predicting, monitoring, and treating this disease.